‘Excellent’ Outcomes After Complete Response in Lymph Node-Positive Breast Cancer
Patients with early lymph node-positive breast cancer and pathologic complete response (pCR) after neoadjuvant therapy had similar long-term recurrence rates and survival regardless of the type of adjuvant therapy they received, a Dutch registry study showed. After a median follow-up of 6 years, regional recurrence rates ranged from 3.0-4.1% whether they had conservative axillary surgery […]
High Rates of pCR With Novel Neoadjuvant Combination for Breast Cancer
SAN ANTONIO — A novel neoadjuvant regimen for HER2-negative breast cancer doubled the pathologic complete response (pCR) rate as compared with standard chemotherapy, a small phase II study showed. Across various breast cancer receptor signatures, pCR rates ranged from 36% to 53% with the combination of paclitaxel, the PD-1 inhibitor cemiplimab (Libtayo), and the investigational […]
Study Suggests Potential to Skip Surgery for Selected Breast Cancer Patients
Women who chose not to have surgery after a pathologic complete response (pCR) to neoadjuvant therapy for early HER2-positive or triple-negative breast cancer (TNBC) had no recurrences during the first 2 years of follow-up, a small prospective study showed. Overall, 31 of 50 (62%) women had no evidence of residual disease by image-guided vacuum-assisted core […]